Technology now allows researchers to easily collect data from people with Parkinson's disease. The data can supplement the details that doctors get from patients during appointments and help researchers develop more efficient clinical trials.
Parkinson's disease is an ideal model system for big data approaches. The Michael J. Fox Foundation (MJFF) offers large datasets to problem-solve big scientific questions in Parkinson's. Our past challenges involve the questions we want to answer in Parkinson's research.
2020 BEAT-PD (Biomarker and Endpoint Assessment to Track Parkinson’s Disease) DREAM Challenge
BEAT-PD was a data challenge designed to benchmark new methods to predict Parkinson’s disease progression. Its objective was to determine whether disease severity and progression can be assessed from passive sensor data collected during daily life. Teams participating in the Challenge had access to raw sensor (accelerometer and gyroscope) time-series data that can be used to predict individual medication state and symptom severity.
2017 Parkinson's Disease Digital Biomarker DREAM Challenge
The Parkinson's Disease Digital Biomarker DREAM Challenge was a first-of-its-kind challenge designed to look for digital Parkinson's biomarkers, which are objective measures to diagnose and track disease. There are currently no Parkinson's biomarkers.
Launched in spring 2017, the DREAM challenge asked experts to analyze data from two studies, including MJFF's Levodopa Response Trial, which evaluated the use of a smartwatch to monitor dyskinesia (uncontrolled, involuntary movements) and "off" periods (times when symptoms return because medication is not working optimally). Funding for the challenge was provided by MJFF and the Robert Wood Johnson Foundation.
Winners, announced in January 2018, developed methods to detect Parkinson's from a walk-and-balance test, as well as to predict the severity of different Parkinson's symptoms using wearables. These approaches could increase the ability to monitor Parkinson's outside of doctors' visits.
2016 PPMI Data Challenge
The Parkinson's Progression Markers Initiative (PPMI) has generated a comprehensive, standardized, longitudinal set of clinical, biological and imaging data unique to the Parkinson's disease field and ripe for novel and innovative exploration. In mid-2016, study sponsor The Michael J. Fox Foundation (MJFF) cast an open call to computational scientists, data scientists and neuroscientists to analyze PPMI data with a view to gaining new insights into Parkinson's diagnosis and progression.
Parkinson's is highly variable, with age of onset, rate of progression, and type and severity of symptoms different among the 6 million people worldwide living with the disease. Identifying models for prognosis and subtyping would aid in subject selection for clinical studies and the design of trials related to novel therapies.
The PPMI Data Challenge, sponsored jointly by PPMI industry partner GE Healthcare and MJFF, offered $50,000 in total prizes ($25,000 per question). The Data Challenge Review Committee comprised MJFF staff and a team of external experts in statistics, data science and Parkinson's disease research. Winners were announced in December 2016.
Read more on the analysis and findings of the winners who answered the following questions:
- What factors are involved in baseline predict clinical progression?
- What are the subtypes of Parkinson's disease?
Watch our webinar of the 2016 PPMI Data Challenge winning submissions, including a detailed description of methods used, summary of results and impact of analysis to the Parkinson's research community.
2013 Data Challenge
In February 2013, The Michael J. Fox Foundation sponsored a $10,000 Data Challenge to spur ideas for using patient data, collected using smartphones, in Parkinson’s disease monitoring and treatment. The winner of the prize — a team from LIONsolver, Inc. developed a “machine learning” approach to tackling the problem.
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.